



Atty Docket No: 098810 027 8741

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

In re the Application of:

Warren, et al.

Serial No.: 09/813,383

Filed: March 20, 2001

Title: PEPTIDE SPECIFICITY OF ANTI-MYELIN  
BASIC PROTEIN AND THE ADMIN-  
ISTRATION OF MYELIN BASIC  
PROTEIN PEPTIDES TO MULTIPLE  
SCLEROSIS PATIENTS

Examiner: Sheridan K. Snedden

Art Unit: 1653

STATEMENT TO SUPPORT FILING AND SUBMISSION OF SUBSTITUTE SEQUENCE  
LISTING IN ACCORDANCE WITH 37 C.F.R. §1.825(a), (b)

Mail Stop Sequence  
Commissioner of Patents  
United States Patent and Trademark Office  
Box 1450

Alexandria, VA 22313-1450

Sir:

In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheets of the Substitute Sequence Listing are supported in the application as filed, on page 10 at lines 20-21. The substitute sheet(s) of the Sequence Listing do not include new matter
2. The substitute copy of the computer readable form, submitted in accordance with 37 CFR 1.825(b), is the same as the amended Substitute Sequence Listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: Sep 16 2003

By: 

Donna O. Perdue  
Reg. No. 51,166

11682 El Camino Real, Suite 200  
San Diego, CA 92130  
Tel. No.: (858) 509-4093  
Fax No.: (858) 509-4010



RECEIVED

SEP 26 2003

TECH CENTER 1600/2500

Format: PatentIn 2.1- Text  
Inventor: WARREN, KENNETH G.  
Title: PEPTIDE SPECIFICITY  
OF ANTI-MYELIN BASIC PROTEIN  
AND THE ADMINISTRATION OF  
MYELIN BASIC PROTEIN PEPTIDES  
TO MULTIPLE SCLEROSIS PATIENTS  
Docket No.: 098810/027 8741  
Serial No.: 09/813,383  
Filed: 2001-03-20  
Recorded: Sept. 16, 2003



## SUBSTITUTE SEQUENCE LISTING

<110> UNIVERSITY OF ALBERTA  
WARREN, KENNETH G.

<120> PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND  
THE ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO  
MULTIPLE SCLEROSIS PATIENTS

<130> 098810/027 8741

<140> 09/813,383

<141> 2001-03-20

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 170

<212> PRT

<213> Homo sapiens

<220>

<221> misc-feature

<223> Human myelin basic protein

<400> 1

Ala	Ser	Gln	Lys	Arg	Pro	Ser	Gln	Arg	His	Gly	Ser	Lys	Tyr	Leu	Ala	
1				5					10					15		
Thr	Ala	Ser	Thr	Met	Asp	His	Ala	Arg	His	Gly	Phe	Leu	Pro	Arg	His	
			20					25					30			
Arg	Asp	Thr	Gly	Ile	Leu	Asp	Ser	Ile	Gly	Arg	Phe	Phe	Gly	Gly	Asp	
		35					40					45				
Arg	Gly	Ala	Pro	Lys	Arg	Gly	Ser	Gly	Lys	Asp	Ser	His	His	Pro	Ala	
	50					55					60					
Arg	Thr	Ala	His	Tyr	Gly	Ser	Leu	Pro	Gln	Lys	Ser	His	Gly	Arg	Thr	
65					70					75				80		
Gln	Asp	Glu	Asn	Pro	Val	Val	His	Phe	Phe	Lys	Asn	Ile	Val	Thr	Pro	
			85						90					95		
Arg	Thr	Pro	Pro	Ser	Gln	Gly	Lys	Gly	Arg	Gly	Leu	Ser	Leu	Ser		
		100					105					110				
Arg	Phe	Ser	Trp	Gly	Ala	Glu	Gly	Gln	Arg	Pro	Gly	Phe	Gly	Tyr	Gly	
		115					120					125				
Gly	Arg	Ala	Ser	Asp	Tyr	Lys	Ser	Ala	His	Lys	Gly	Phe	Lys	Gly	Val	
	130					135					140					
Asp	Ala	Gln	Gly	Thr	Leu	Ser	Lys	Ile	Phe	Lys	Leu	Gly	Gly	Arg	Asp	
145					150					155					160	
Ser	Arg	Ser	Gly	Ser	Pro	Met	Ala	Arg	Arg							
				165					170							

RECEIVED

SEP 26 2003

TECH CENTER 1600/2500

<210> 2  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2  
Val His Phe Phe Lys Asn Ile  
1 5

<210> 3  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 3  
Lys Ser His Gly Arg Thr Gln Asp Glu Asn Pro Val Val His Phe Phe  
1 5 10 15

Lys Asn Ile Val Thr  
20

<210> 4  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 4  
Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser His Gly  
1 5 10 15

<210> 5  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 5  
His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys  
1 5 10 15

<210> 6  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 6  
Tyr Gly Ser Leu Pro Gln Lys Ser His Gly Arg Thr Gln Asp Glu  
1 5 10 15

<210> 7  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 7  
Thr Gln Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr  
1 5 10 15

Pro Arg

<210> 8  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide  
  
 <400> 8  
 Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys Gly  
   1                  5                  10                  15

<210> 9  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide

<400> 9  
 Asn Pro Val Val His Phe Phe Lys Asn Ile  
   1                  5                  10

<210> 10  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide

<400> 10  
 Pro Val Val His Phe Phe Lys Asn Ile Val  
   1                  5                  10

<210> 11  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide

<400> 11  
 Val Val His Phe Phe Lys Asn Ile Val Thr Pro  
   1                  5                  10

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 12  
Val His Phe Phe Lys Asn Ile Val Thr Pro  
1 5 10